Arquivos brasileiros de endocrinologia e metabologia · 2014
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Barros Joelma Ines Tagliapietra, Fechine Francisco Vagnaldo, Montenegro Júnior Renan Magalhães, Vale Otoni Cardoso do, Fernandes Virgínia Oliveira, Souza Marcellus Henrique Loiola Ponte de, Cunha Gilmara Holanda da, Moraes Manoel Odorico de, d'Alva Catarina Brasil, Moraes Maria Elisabete Amaral de
Аннотация
OBJECTIVE: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.
MATERIALS AND METHODS: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).
RESULTS: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.
CONCLUSION: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.
MATERIALS AND METHODS: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).
RESULTS: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.
CONCLUSION: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.
Предметные рубрики MeSH
Activation, MetabolicAdultAlanine TransaminaseArea Under CurveAspartate AminotransferasesBlood GlucoseCholesterolDiabetes Mellitus, Type 2Evoked Potentials, SomatosensoryFastingFemaleFood, FormulatedGlucagon-Like Peptide 1Glycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedProspective StudiesPyrazinesSitagliptin PhosphateStatistics, NonparametricTriazolesTriglyceridesgamma-Glutamyltransferase